Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models

Brain Research

Volumn 1547, Issue , 2014, Pages 49-57

  Bao, Xiu Qi ^a   Kong, Xiang Chen ^a   Kong, Li Bing ^b   Wu, Liang Yu ^a   Sun, Hua ^a   Zhang, Dan ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Liaoning Dianli Central Hospital   (China)

Author keywords

Akt; FLZ; Parkinson's disease; Tyrosine hydroxylase; synuclein

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; MEMBRANE PROTEIN; N [2 (4 HYDROXYPHENYL)ETHYL] 2 (2,5 DIMETHOXYPHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL)ACRYLAMIDE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN RTP801; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION;

RATTUS;

6-HYDROXYDOPAMINE; 6-OHDA; AKT; CO-IMMUNOPRECIPITATION; CO-IP; FLZ; PARKINSON'S DISEASE; PD; PHOSPHOINOSITIDE-3-KINASE; PI3K; TH; TYROSINE HYDROXYLASE; Α-SYN; Α-SYNUCLEIN;

ALPHA-SYNUCLEIN; ANIMALS; APOMORPHINE; BENZENEACETAMIDES; CELL DEATH; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PHENOLS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TYROSINE 3-MONOOXYGENASE;

EID: 84892915464     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.12.026     Document Type: Article

References (26)

1. X.Q. Bao, X.C. Kong, C. Qian, and D. Zhang FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models Neuroscience 2012 396 404
2. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron The Akt-GSK-3 signaling cascade in the actions of dopamine Trends Pharmacol. Sci. 28 2007 166 172
3. F. Blandini, M.T. Armentero, and E. Martignoni The 6-hydroxydopamine model: news from the past Parkinsonism Relat. Disord. 14 2008 S124 S129
4. J.Y. Chung, S.J. Lee, S.H. Lee, Y.S. Jung, N.C. Ha, W. Seol, and B.J. Park Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease Neurosignals 19 2011 86 96
5. M. Coulpier, and C.F. Ibáñez Retrograde propagation of GDNF-mediated signals in sympathetic neurons Mol. Cell. Neurosci. 27 2004 132 139
6. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
7. S. Gandhi, and N.W. Wood Molecular pathogenesis of Parkinson's disease Hum. Mol. Genet. 14 2005 2749 2755
8. B.G. Garcia, Y. Wei, J.A. Moron, R.Z. Lin, J.A. Javitch, and A. Galli Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution Mol. Pharmacol. 68 2005 102 109
9. S.Y. Kao Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors Biochem. Biophys. Res. Commun. 385 2009 434 438
10. S.R. Kim, V. Ries, H.C. Cheng, T. Kareva, T.F. Oo, W.H. Yu, K. Duff, N. Kholodilov, and R.E. Burke Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling Neurobiol. Dis. 44 2011 215 222
11. X.C. Kong, D. Zhang, C. Qian, G.T. Liu, and X.Q. Bao FLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP(+) Brain Res. 1383 2011 99 107
12. Y.H. Li, N. Gao, Y.W. Ye, X. Li, S. Yu, H. Yang, K. Uéda, and P. Chan Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase Acta Neurol. Belg. 111 2011 130 135
13. J.H. Lim, K.M. Kim, S.W. Kim, O. Hwang, and H.J. Choi Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage Pharmacol. Res. 57 2008 325 331
14. C. Malagelada, E.J. Ryu, S.C. Biswas, V. Jackson-Lewis, and L.A. Greene RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation J. Neurosci. 26 2006 9996 10005
15. V.D. Nair, and C.W. Olanow Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses J. Biol. Chem. 283 2008 15469 15478
16. X.M. Peng, R. Tehranian, P. Dietrich, L. Stefanis, and R.G. Perez Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells J. Cell. Sci. 118 2005 3523 3530
17. V. Ries, C. Henchcliffe, T. Kareva, M. Rzhetskaya, R. Bland, M.J. During, N. Kholodilov, and R.E. Burke Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease Proc. Natl. Acad. Sci. U S A 103 2006 18757 18762
18. J.H. Seo, J.C. Rah, S.H. Choi, J.K. Shin, K. Min, H.S. Kim, C.H. Park, S. Kim, E.M. Kim, SH. Lee, S. Lee, S.W. Suh, and Y.H. Suh Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway FASEB J. 16 2002 1826 1828
19. Y. Tasaki, T. Omura, T. Yamada, T. Ohkubo, M. Suno, S. Iida, T. Sakaguchi, M. Asari, K. Shimizu, and K. Matsubara Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells Brain Res. 1344 2010 25 33
20. S. Timmons, M.F. Coakley, A.M. Moloney, and C. O' Neill Akt signal transduction dysfunction in Parkinson's disease Neurosci. Lett. 467 2009 30 35
21. J. Xu, S.Y. Kao, F.J.S. Lee, W. Song, L.W. Jin, and B.A. Yankner Dopaminedependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease Nat. Med. 8 2002 600 606
22. Y. Yang, S. Gehrke, M.E. Haque, Y. Imai, J. Kosek, L. Yang, M.F. Beal, I. Nishimura, K. Wakamatsu, S. Ito, R. Takahashi, and B. Lu Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling Proc. Natl. Acad. Sci. U S A 102 2005 13670 13675
23. S. Yu, X. Zuo, Y. Li, C. Zhang, M. Zhou, Y.A. Zhang, K. Uéda, and P. Chan Inhibition of tyrosine hydroxylase expression in alpha-synuclein- transfected dopaminergic neuronal cells Neurosci. Lett. 367 2004 34 39
24. D. Zhang, X. Hu, S.J. Wei, J. Liu, H. Gao, L. Qian, B. Wilson, G Liu, and J.S. Hong Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity J. Neuroinflammation 5 2008 21
25. D. Zhang, J.J. Zhang, and G.T. Liu The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells Neuropharmacology 52 2007 423 429
26. D. Zhang, J.J. Zhang, and G.T. Liu The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells Eur. J. Pharmacol. 561 2007 1 6